Sage Journals: Discover world-class research

Abstract

Dopamine and serotonin are produced by distinct groups of neurons in the brain, and gene therapies other than direct injection have not been attempted to correct congenital deficiencies in such neurotransmitters. In this study, we performed gene therapy to treat knock-in mice with dopamine and serotonin deficiencies caused by a mutation in the aromatic l-amino acid decarboxylase (AADC) gene (Ddc^KI mice). Intracerebral ventricular injection of neonatal mice with an adeno-associated virus (AAV) serotype 9 (AAV9) vector expressing the human AADC gene (AAV9-hAADC) resulted in widespread AADC expression in the brain. Without treatment, 4-week-old Ddc^KI mice exhibited whole-brain homogenate dopamine and serotonin levels of 25% and 15% of normal, respectively. After gene therapy, the levels rose to 100% and 40% of normal, respectively. The gene therapy improved the growth rate and survival of Ddc^KI mice and normalized their hindlimb clasping and cardiovascular dysfunctions. The behavioral abnormalities of the Ddc^KI mice were partially corrected, and the treated Ddc^KI mice were slightly more active than normal mice. No immune reactions resulted from the treatment. Therefore, a congenital neurotransmitter deficiency can be treated safely through inducing widespread expression of the deficient gene in neonatal mice.

Get full access to this article

View all access options for this article.

References

Abeling

N.G.

, Van Gennip

A.H.

, Barth

P.G.

, et al. (1998). Aromatic L-amino acid decarboxylase deficiency: a new case with a mild clinical presentation and unexpected laboratory findings. J. Inherit. Metab. Dis., 21, 240–242.

Brautigam

, Wevers

R.A.

, Hyland

, et al. (2000). The influence of L-dopa on methylation capacity in aromatic L-amino acid decarboxylase deficiency: biochemical findings in two patients. J. Inherit. Metab. Dis., 23, 321–324.

Brun

, Ngu

L.H.

, Keng

W.T.

, et al. (2010). Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology, 75, 64–71.

Cearley

C.N.

, Vandenberghe

L.H.

, Parente

M.K.

, et al. (2008). Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther., 16, 1710–1718.

Chtarto

, Bockstael

, Tshibangu

, et al. (2013). A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting. Br. J. Clin. Pharmacol., 76, 217–232.

Ciesielska

, Hadaczek

, Mittermeyer

, et al. (2013). Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol. Ther., 21, 158–166.

Crawley

J.N.

, Belknap

J.K.

, Collins

, et al. (1997). Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl), 132, 107–124.

Cressant

, Desmaris

, Verot

, et al. (2004). Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci., 24, 10229–10239.

Fiumara

, Brautigam

, Hyland

, et al. (2002). Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies. Neuropediatrics, 33, 203–208.

10.

Foust

K.D.

, Nurre

, Montgomery

C.L.

, et al. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol., 27, 59–65.

11.

Gadalla

K.K.

, Bailey

M.E.

, Spike

R.C.

, et al. (2013). Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice. Mol. Ther., 21, 18–30.

12.

Hamosh

, and Mckusick

V.A.

(2011). DOPA DECARBOXYLASE; DDC. OMIM Database, Johns Hopkins University, Baltimore, MD.

13.

Homanics

G.E.

, Quinlan

J.J.

, and Firestone

L.L.

(1999). Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines. Pharmacol. Biochem. Behav., 63, 21–26.

14.

Hwu

W.L.

, Muramatsu

, Tseng

S.H.

, et al. (2012). Gene therapy for aromatic L-amino acid decarboxylase deficiency. Sci. Transl. Med., 4, 134ra61.

15.

Hyland

, and Clayton

P.T.

(1990). Aromatic amino acid decarboxylase deficiency in twins. J. Inherit. Metab. Dis., 13, 301–304.

16.

Hyland

, Surtees

R.A.

, Rodeck

, and Clayton

P.T.

(1992). Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology, 42, 1980–1988.

17.

Kim

J.Y.

, Ash

R.T.

, Ceballos-Diaz

, et al. (2013). Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in vivo . Eur. J. Neurosci., 37, 1203–1220.

18.

Korenke

G.C.

, Christen

H.J.

, Hyland

, et al. (1997). Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur. J. Paediatr. Neurol., 1, 67–71.

19.

Lee

N.C.

, Shieh

Y.D.

, Chien

Y.H.

, et al. (2013). Regulation of the dopaminergic system in a murine model of aromatic l-amino acid decarboxylase deficiency. Neurobiol. Dis., 52C, 177–190.

20.

Lin

C.J.

, Tai

, Huang

M.T.

, et al. (2010). Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J. Neurochem., 114, 717–727.

21.

Maller

, Hyland

, Milstien

, et al. (1997). Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J. Child Neurol., 12, 349–354.

22.

Manegold

, Hoffmann

G.F.

, Degen

, et al. (2009). Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J. Inherit. Metab. Dis., 32, 371–380.

23.

Miyake

, Miyake

, Yamamoto

, et al. (2011). Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors. Brain Res., 1389, 19–26.

24.

Montioli

, Oppici

, Cellini

, et al. (2013). S250F variant associated with aromatic amino acid decarboxylase deficiency: molecular defects and intracellular rescue by pyridoxine. Hum. Mol. Genet., 22, 1615–1624.

25.

Patel

B.A.

, Arundell

, Parker

K.H.

, et al. (2005). Simple and rapid determination of serotonin and catecholamines in biological tissue using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 818, 269–276.

26.

Pons

, Ford

, Chiriboga

C.A.

, et al. (2004). Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology, 62, 1058–1065.

27.

Rahim

A.A.

, Wong

A.M.

, Hoefer

, et al. (2011). Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J., 25, 3505–3518.

28.

Rozas

, Guerra

M.J.

, and Labandeira-Garcia

J.L.

(1997). An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res. Brain Res. Protoc., 2, 75–84.

29.

Swoboda

K.J.

, Hyland

, Goldstein

D.S.

, et al. (1999). Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology, 53, 1205–1211.

30.

Swoboda

K.J.

, Saul

J.P.

, Mckenna

C.E.

, et al. (2003). Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann. Neurol., 54 Suppl. 6, S49–S55.

31.

Tay

S.K.

, Poh

K.S.

, Hyland

, et al. (2007). Unusually mild phenotype of AADC deficiency in 2 siblings. Mol. Genet. Metab., 91, 374–378.

32.

Verbeek

M.M.

, Geurtz

P.B.

, Willemsen

M.A.

, and Wevers

R.A.

(2007). Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes. Mol. Genet. Metab., 90, 363–369.

33.

Vuckovic

M.G.

, Li

, Fisher

, et al. (2010). Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with [(1)F]fallypride. Mov. Disord., 25, 2777–2784.

34.

Wassenberg

, Willemsen

M.A.

, Geurtz

P.B.

, et al. (2010). Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox. Mol. Genet. Metab., 101, 349–356.

35.

W.L.

, Lin

Y.W.

, Min

M.Y.

, and Chen

C.C.

(2010). Mice lacking Asic3 show reduced anxiety-like behavior on the elevated plus maze and reduced aggression. Genes Brain Behav., 9, 603–614.

36.

Zeiss

C.J.

(2005). Neuroanatomical phenotyping in the mouse: the dopaminergic system. Vet. Pathol., 42, 753–773.

37.

Zolotukhin

, Potter

, Zolotukhin

, et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods, 28, 158–167.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.46 MB

0.23 MB

0.15 MB

0.45 MB

9.97 MB

Treatment of Congenital Neurotransmitter Deficiencies by Intracerebral Ventricular Injection of an Adeno-Associated Virus Serotype 9 Vector

Abstract

Get full access to this article

References

Supplementary Material